𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of neuroblastoma with131I-metaiodobenzylguanidine: Experience of the Münster/Kassel group

✍ Scribed by Fischer, M. ;Wehinger, H. ;Kraus, C. ;Ritter, J. ;Schröter, W.

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
205 KB
Volume
15
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

I-131-metaiodobenzylguanidine was used for treatment of neuroblastoma stage IV in three children after surgery and or chemotherapy had failed to be effective. In two of the children with multilocular lesions, after an impressive improvement of clinical symptoms tumor progression was observed. Because in about 25% of children with relapsing neuroblastoma complete remission may be achieved by combining surgery, chemotherapy, and I-131-MIBG treatment, this therapeutic modality should be included in the therapeutic strategy of stage III and IV neuroblastoma.

📜 SIMILAR VOLUMES

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine
✍ Troncone, L. ;Riccardi, R. ;Montemaggi, P. ;Rufini, V. ;Lasorella, A. ;Mastrange 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB

Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity 131I-metaiodobenzylguanidine (131I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an app

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine: The experience of an Italian study group
✍ Bestagno, M. ;Guerra, P. ;Puricelli, G. P. ;Colombo, L. ;Calculli, G. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Eight patients affected by neuroblastoma were treated with 18 courses of 131I-meta-iodobenzylguanidine (MIBG). They all had been judged as "nonresponders" to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow

131I-metaiodobenzylguanidine treatment i
131I-metaiodobenzylguanidine treatment in neuroblastoma: Report of two cases
✍ Cottino, F. ;Mussa, G. C. ;Madon, E. ;Favero, A. ;Silvestro, L. ;Grazia, G. 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

Poor results with 131I-meta-iodobenzylguanidine (MIBG) therapy have been obtained in two children with stage IV neuroblastoma treated after partial surgery and unsatisfactory combination chemotherapy. Both patients' response to treatment (four and three 1-month-spaced courses, respectively; cumulati

Position paper: Role of131I-metaiodobenz
Position paper: Role of131I-metaiodobenzylguanidine in the treatment of neuroblastoma
✍ Mastrangelo, Renato; Tornesello, Assunta; Mastrangelo, Stefano 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 1 views

Background. Standard chemo-radiotherapy methods for the treatment of children with advanced neuroblastoma (NBL) including bone marrow transplant approaches have been disappointing. These poor results can be ascribed to the evolution of residual drug-resistant cell populations. Curative attempts shou

Considerations on131I-metaiodobenzylguan
Considerations on131I-metaiodobenzylguanidine therapy of six children with neuroblastoma
✍ Sanguineti, Michele 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

Six children affected by neuroblastoma at stages III and IV were treated with high-specific-activity 131I-metaiodobenzylguanidine (MIBG). After 131I-MIBG treatment three patients died at 12, 10, and 12 weeks, respectively; the other three were still living at 21, 16, and 24 weeks, respectively. Alth